Jump to content

Irinotecan hydrochloride nanoliposomal injections


Dandygal76

Recommended Posts

Okay, I was looking at a spreadsheet from NICE this week that indicated this will be licensed in UK from January (note to everyone this was licensed in US last year - how disgraceful).


I need experiences as I think this is in private healthcare here... (W&M please be reading this in case). So a) I need personal experiences if they are out there b) I want to know is the 6.1 median survival from the point of 2nd line treatment or is it from the start of PC c) is this something to be considered with dad instead of Furry Fox.


PCUK nurses... would love some input on this. I think dad is going to come off the trial in December... he wants to nuke the blasted thing and not wait for growth. The trial sort of said it would be good time to step away as it can become immune to current treatment and if he steps away now he can come back later. They have someone who is 8 months on with no progression and no treatment. Dad is not there though to take that risk, he wants nano and so cannot go back to the trial. I think we will ditch trial in December after scan (if just stable... we will not do this if shrinking). Oh, I think I forgot to say properly last scan outcome we have stable disease sort of... a couple of mm shrinkage but who knows who was reading the 'difficult to read' scan this time. I will pay for a second opinion this week from professor nano.


I know my dad and I am pretty sure we are about to say goodbye to Sarah Cannon. This is fine of course, think outside of the box and be bold... what the hell else is there to lose. I just feel that the PC life is steering away from the furry fox?


To get a different outcome, we need to think differently. I am torn on what to advise my lovely dad. I think my head is stuck in folfirinox as there have been some great outcomes and I am scared to 'think differently'. x

Link to comment
Share on other sites

Hey DG,

b) the 6.1 median survival is from the point of the 2nd line treatment.

c) the ASCO practice guidelines (see https://pilotguidelines.atlassian.net/wiki/plugins/servlet/mobile?contentId=4849666#content/view/68091910) recommend that first line Gem/Abrax be followed by 2nd line Fluorouracil plus oxaliplatin, irinotecan, or nanoliposomal irinotecan (recommendation 3.2). This concoction is similar to, but not the same as Folfirinox. I don't know the rationale behind it but maybe your oncologist can advise.


W&M xx

Link to comment
Share on other sites

Oh and " irinotecan hydrochloride nanoliposomal injections" is another name for Onivyde which has its own short thread earlier in the Treatments forum. Don't know if there's an easy way to merge the two threads to save confusion? (this question is addressed to DG and/or the mod).

Link to comment
Share on other sites

  • 2 weeks later...

I will look into this more tomorrow as just got in... it is very disappointing if this is the decision. Perhaps I will try an online petition but I have seen some around for Abraxane that do not go far. Maybe worth a try though... what is there to lose. x

Link to comment
Share on other sites

It's World Pancreatic Cancer day today. How sad that NICE is once again poised to deny a new treatment to PC patients in NHS England. First Abraxane, now Onivyde. Plus there's the lack of support from NICE for NanoKnife. Talk about kicking people when they're down.

Link to comment
Share on other sites

W & M I have posted the consultation page in every nook and cranny on the internet and forums I can find and I am still going. I know they say #wagehope but today it is #wagewar!

Link to comment
Share on other sites

Nadia - Support Team

Hi all,


Pancreatic Cancer UK is preparing responses to current consultations about Onivyde and will be considering all comments on this thread when doing so, so please keep them coming.


Kevin Armstrong

Head of Policy and Campaigns (Maternity Cover)

Link to comment
Share on other sites

Hi Kevin, I'm very disappointed by this new recommendation from NICE as it's another step on the path to England becoming a backwater for PC treatment. Compared to other European countries our survival rates are already poor and we're going to be left further and further behind.

I do appreciate that there are cost and value for money considerations and if it was a choice between Abraxane and Onivyde I would choose Abraxane. Abraxane is now standard of care elsewhere and I think it's shocking that it's still not available in England. One of the reasons for the NICE Onivyde ruling is that the trial comparator was 5- FU/LV and this is not standard of care in 2nd line treatment here. I literally gasped when I read this in the NICE report as WE DON'T EVEN HAVE A 2ND LINE STANDARD OF CARE. And that's partly due to people being denied Abraxane for 1st line.


A very cross W&M.

Link to comment
Share on other sites

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now
×
×
  • Create New...

Important Information

We have placed cookies on your device to help make this website better. You can adjust your cookie settings, otherwise we'll assume you're okay to continue. By using our forums you agree to our Terms of Use and Privacy Policy.